Thrive Capital
PulseAugur coverage of Thrive Capital — every cluster mentioning Thrive Capital across labs, papers, and developer communities, ranked by signal.
- 2024-02-13 funding Thrive Capital invested in 17 other venture capital firms from its growth fund. 来源
3 天有情绪数据
Thrive Capital's focus on AI across defense and health tech
Thrive Capital's recent lead investments in both Anduril (defense tech) and Isomorphic Labs (drug discovery) highlight a strategic focus on AI applications within critical sectors. This pattern suggests a deliberate investment thesis centered on AI's transformative potential in areas with high societal and economic impact.
Thrive Capital to invest in health tech beyond drug discovery
Following their investment in AI-driven drug discovery firm Isomorphic Labs and prescription processing company Forus, Thrive Capital may expand its health tech portfolio. Their demonstrated interest in AI's application to healthcare suggests potential future investments in other AI-powered health tech sub-sectors.
Thrive Capital to lead another major AI funding round within 30 days
Thrive Capital has recently led significant funding rounds for two prominent AI-driven companies, Isomorphic Labs and Anduril. Given their demonstrated appetite for backing high-growth AI ventures and their lead role in Isomorphic's upcoming round, it's probable they will lead another substantial AI funding round in the near future.
-
Anduril融资50亿美元，估值610亿美元，得益于五角大楼采购提速
国防科技初创公司Anduril已完成E轮融资50亿美元，估值达到610亿美元。这一估值较之前翻倍，主要归因于美国政府采购速度的转变。Anduril的AI指挥软件Lattice被用于多个国防项目，其快速的软件优先开发模式与新的、更快的合同流程相契合。
-
Isomorphic Labs 和 Anduril 融资数十亿美元，AI 进步是主要驱动力
Isomorphic Labs 是一家由人工智能驱动的药物发现公司，Anduril 是一家国防科技公司，两者近期都获得了巨额融资。Isomorphic 在 B 轮融资中筹集了 21 亿美元，而 Anduril 在 H 轮融资中以 610 亿美元的估值完成了 50 亿美元的融资。Thrive Capital 是两轮融资的主要投资者，Andreessen Horowitz 也是 Anduril 融资的领投方。两家公司都在利用人工智能的进步…
-
Forus 凭借人工智能驱动的处方处理服务估值达 10 亿美元
Forus 是一家健康科技初创公司，现已达到 10 亿美元的估值，并获得了 1.6 亿美元的融资，以解决处方无人领取的重大问题。该公司利用人工智能简化处方处理的后台管理，确保患者更有效地获得药物。其技术协助医疗机构应对复杂的保险流程，提高处方领取率，目前已有数千家机构依赖其系统。
-
Isomorphic Labs eyes $2B+ funding as Sinovac Biotech posts modest sales gain amid losses
Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind, is reportedly in advanced talks to raise over $2 billion in a new funding round. Thrive Capital, which led Isomorphic Labs' initial fundi…
-
Google DeepMind衍生公司Isomorphic Labs为AI药物试验筹集21亿美元
Isomorphic Labs是一家由Google DeepMind孵化的人工智能驱动的药物发现公司，已在B轮融资中获得超过20亿美元。这笔巨额投资由Thrive Capital领投，将用于扩展其专有的药物设计引擎IsoDDE，并将其候选药物管线推进到人体临床试验阶段。该公司利用DeepMind的AlphaFold技术来预测蛋白质结构并设计高效、低副作用的药物。
-
OpenAI takes an ownership stake in Thrive Holdings to accelerate enterprise AI adoption
OpenAI has taken an ownership stake in Thrive Holdings to accelerate the adoption of AI within enterprises. The partnership will focus initially on accounting and IT services, embedding OpenAI's research, product, and e…
-
Thrive Capital 通过成长基金投资了 17 家风投公司
由 Joshua Kushner 领导的 Thrive Capital 已使用其 33 亿美元的第八期成长阶段基金，投资了至少 17 家其他风险投资公司。这些通过《财富》杂志获取的邮件披露的投资，包括支持由 Scale AI 首席执行官 Alexandr Wang 和通讯作者 Packy McCormick 等新兴管理人创立的新公司。这类投资并不常见，通常由大型风投公司进行，以增强交易流动性、支持网络联系或作为善意姿态，但它们也伴随着…